Inventiva granted patent for lanifibranor by USPTO

Inventiva announced that the United States Patent and Trademark Office, or USPTO, granted a patent that protects the use of lanifibranor for the treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage. This patent will expire on November 8, 2039. The company said, "This new patent further strengthens Inventiva’s patent portfolio for lanifibranor, the company’s lead product candidate, in the United States, which already comprised patents protecting the use of lanifibranor to treat several diseases including non-alcoholic steatohepatitis and fibrotic diseases. This patent further expands the intellectual property protection of lanifibranor in the United States for use in patients with cirrhotic NASH."